MK 1809
Alternative Names: MK-1809Latest Information Update: 17 Mar 2010
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Cardiovascular therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders